@article{72e0872e879242d697d89785c2c6794b,
title = "Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia",
abstract = "The prevalence of dyslipidaemia has been increasing in the Asia-Pacific region and this is attributed to dietary changes and decreasing physical activity. While there has been substantial progress in dyslipidaemia therapy, its management in the region is hindered by limitations in awareness, adherence and healthcare costs. The Asian Pacific Society of Cardiology (APSC) developed these consensus recommendations to address the need for a unified approach to managing dyslipidaemia. These recommendations are intended to guide general cardiologists and internists in the assessment and treatment of dyslipidaemia and are hoped to pave the way for improving screening, early diagnosis and treatment. The APSC expert panel reviewed and appraised the evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Consensus recommendations were developed, which were then put to an online vote. The resulting consensus recommendations tackle contemporary issues in the management of dyslipidaemia, familial hypercholesterolaemia and lipoprotein(a) in the Asia-Pacific region.",
keywords = "Asia-Pacific, Consensus, Dyslipidaemia, Familial hypercholesterolaemia, Lipoprotein(a)",
author = "Natalie Koh and Ference, {Brian A.} and Nicholls, {Stephen J.} and Navar, {Ann Marie} and Chew, {Derek P.} and Karam Kostner and Ben He and Tse, {Hung Fat} and Jamshed Dalal and Anwar Santoso and Junya Ako and Hayato Tada and Park, {Jin Joo} and Ong, {Mei Lin} and Eric Lim and Tavin Subramaniam and Li, {Yi Heng} and Arintaya Phrommintikul and Iyengar, {S. S.} and Saumitra Ray and Park, {Kyung Woo} and Tan, {Hong Chang} and Narathip Chunhamaneewat and Yeo, {Khung Keong} and Tan, {Jack Wei Chieh}",
note = "Funding Information: Disclosure: This work was funded through Asian Pacific Society of Cardiology by unrestricted educational grants from Abbott Vascular, Amgen, AstraZeneca, Bayer and Roche Diagnostics. JWCT has received honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Alvimedica, Boehringer Ingelheim and Pfizer; research and educational grants from Medtronic, Biosensors, Biotronik, Philips, Amgen, AstraZeneca, Roche, Ostuka, Terumo and Abbott Vascular; and consulting fees from Elixir and CSL Behring. JWCT is on the European Cardiology Review editorial board; this did not influence peer review. AMN has received research funding from BMS, Esperion, Amgen and Janssen; and honoraria and consulting fees from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim , Esperion, Janssen, Lilly, Sanofi, Regeneron, NovoNordisk, Novartis, The Medicines Company, New Amsterdam, 89Bio and Pfizer. MLO has received consulting fees, lecture fees and travel grants from Abbott, Asian Pacific Society of Cardiology, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini, MSD, Novartis, Novo Nordisk, Pfizer and Sanofi. HFT has received grants, research support, speakers bureau, honoraria or consulting fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Medtronic, Novartis, Pfizer and Sanofi. SSI has received investigator fees from Amgen and lecture honoraria from Reddy{\textquoteright}s Lab, Sanofi, and Novartis. TS has received advisory board honoraria from Amgen, AstraZeneca, MSD, Novo Nordisk, Pfizer, Novartis and Sanofi. SJN has received research support from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience; and is a consultant for AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion and Boehringer Ingelheim. KKY has received institutional research funding from Medtronic, Boston Scientific, Amgen, AstraZeneca and Shockwave Medical; consulting or honoraria fees from Medtronic, Boston Scientific, Abbott Vascular, Amgen, Bayer and Novartis; and speaker or proctor fees from Abbott Vascular, Boston Scientific, Medtronic, Philips, Shockwave Medical, Alvimedica, Menarini, AstraZeneca, Amgen and Bayer. All other authors have no conflicts of interest to declare. Acknowledgements: Medical writing support was provided by Agnes Agustin and Ivan Olegario of MIMS Pte Ltd. Received: 15 July 2021 Accepted: 4 October 2021 Citation: European Cardiology Review 2021;16:e54. DOI: https://doi.org/10.15420/ecr.2021.36 Correspondence: Jack Wei Chieh Tan, National Heart Centre, Singapore, 5 Hospital Dr, Singapore 169609. E: jack.tan.w.c@singhealth.com.sg Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. Publisher Copyright: {\textcopyright} 2021 Radcliffe Group Ltd. All rights reserved.",
year = "2021",
doi = "10.15420/ECR.2021.36",
language = "English (US)",
volume = "16",
journal = "European Cardiology Review",
issn = "1758-3756",
publisher = "Radcliffe Publishing Ltd.",
}